查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1866352

药物释放型植入市场－2025-2030年预测

Drug Eluting Implants Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到 2025 年，药物释放型植入市场规模将达到 75.61 亿美元，到 2030 年将达到 101.33 亿美元，复合年增长率为 6.03%。

由于药物洗脱植入物能够以可控的释放速率将活性药物成分（API）直接输送到目标组织，从而提高疗效并最大限度地减少副作用，预计全球药物释放型植入市场将迎来显着增长。植入，尤其是药物释放型支架（DES），优于传统的口服或肠外给药方式，并正日益广泛地应用于糖尿病、癌症、避孕、爱滋病预防、慢性疼痛、心臟病和中枢神经系统疾病的治疗。关键成长要素包括慢性病盛行率的上升、全球人口老化、研发投入的增加。儘管高昂的研发成本为市场带来了挑战，但病患接受度的提高和技术的进步正为其带来益处。

市场驱动因素

糖尿病患者数量增加

全球糖尿病盛行率的快速成长是药物释放型植入市场的主要驱动力。这些植入因其在糖尿病管理中的癒合特性而日益普及，能够提供标靶药物输送，从而改善患者的治疗效果。国际糖尿病联盟（IDF）预测，到2045年，20至79岁糖尿病患者人数预计将达到7.02亿，与过去几年相比显着增长。患者群体的成长预计将推动对药物释放型植入的需求不断增长，其精准的药物输送机制有助于有效控制疾病，并将在2030年前推动市场扩张。

癌症发生率增加

全球癌症发生率的不断攀升显着扩大了药物释放型植入的市场，尤其是在化疗领域。这些植入提供了一种微创且影像引导的给药途径，从而提高了治疗的精确度。癌症病例的增加导致全球化疗疗程的增加，进一步印证了这类植入的需求。它们能够在最大限度减少对健康组织损伤的同时，精准输送标靶治疗，使其成为肿瘤治疗领域的重要工具，并将在预测期内进一步推动市场成长。

人口老化

根据联合国估计，到2050年，全球老年人口预计将翻一番，达到15亿，这将成为推动市场成长的主要因素。随着老年人更容易患上需要药物释放型植入的疾病，例如心血管疾病和癌症，市场需求将会增加。这种人口结构变化正在推动对先进治疗方法的需求，使药物释放型植入成为与老龄化相关的健康挑战的关键解决方案。

区域展望

由于人口老化加剧以及糖尿病和癌症发病率上升，亚太地区预计将迎来显着的市场成长。儘管北美和欧洲凭藉其高普及率和先进的医疗基础设施将继续主导，但亚太地区医疗技术的快速发展和庞大的患者群体将巩固其在2030年前作为高成长地区的地位。

竞争格局

包括iVascular、ProMed Pharma, LLC、强生公司、波士顿科学公司、默克集团、美敦力公司、Biosensors International Group、雅培公司、Elixir Medical Corporation和西门子医疗在内的主要企业正透过策略伙伴关係和产品研发推动创新。例如，2023年5月，iVascular的iCover球囊扩张型覆膜支架获得CE核准，拓展了血管治疗的选择范围。

市场展望

受慢性病盛行率上升、人口老化以及研发进步的推动，药物释放型植入市场预计到2030年将保持强劲成长。北美和欧洲市场的主导地位，以及亚太地区的快速扩张，凸显了该市场的全球潜力。相关人员必须专注于创新和扩充性，以满足不断增长的需求，同时应对成本方面的挑战。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

  • 历史资料（2022-2024 年）和预测资料（2025-2030 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

第五章 依产品类型药物释放型植入市场

  • 介绍
  • 药物释放型支架
  • 避孕植入
  • 药物释放型血管移植物
  • 其他的

第六章 依材料分類的药物释放型植入市场

  • 介绍
  • 可生物降解
  • 不可生物降解

第七章 依应用分類的药物释放型植入市场

  • 介绍
  • 肿瘤学
  • 眼科
  • 心臟病学
  • 避孕和生育管理
  • 其他的

第八章 依最终使用者分類的药物释放型植入市场

  • 介绍
  • 医院
  • 门诊手术中心
  • 其他的

第九章 按地区分類的药物释放型植入市场

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 台湾
    • 其他的

第十章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十一章 公司简介

  • iVascular
  • ProMed Pharma
  • Boston Scientific Corporation
  • Merck Group
  • Medtronic, Inc.
  • Biosensors International Group
  • Abbott Laboratories
  • Elixir Medical Corporation
  • Biotronik SE & Co. KG
  • Lubrizol

第十二章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061611191

The Drug Eluting Implants Market is forecasted to advance from USD 7.561 billion in 2025 to USD 10.133 billion by 2030, at a CAGR of 6.03%.

The global drug-eluting implants market is poised for significant growth, driven by their ability to deliver controlled-release active pharmaceutical ingredients (APIs) directly to targeted tissues, enhancing treatment efficacy while minimizing side effects. These implants, notably drug-eluting stents (DES), outperform traditional oral or parenteral drug delivery methods and are increasingly adopted for managing conditions such as diabetes, cancer, contraception, HIV/AIDS prevention, chronic pain, cardiology, and central nervous system disorders. Key growth drivers include the rising prevalence of chronic diseases, an aging global population, and increased R&D investments. The market faces challenges from high development costs but benefits from growing patient adoption and technological advancements.

Market Drivers

Rising Prevalence of Diabetes

The global surge in diabetes cases is a major catalyst for the drug-eluting implants market. These implants are increasingly utilized for their healing properties in diabetes management, offering targeted drug delivery to improve patient outcomes. The International Diabetes Federation projects that the number of people with diabetes aged 20-79 will reach 700,002 by 2045, up significantly from previous years. This growing patient population is expected to drive demand for drug-eluting implants, as their precise delivery mechanisms support effective disease management, fueling market expansion through 2030.

Increasing Cancer Incidence

The rising global incidence of cancer significantly boosts the market for drug-eluting implants, particularly in chemotherapy applications. These implants provide a minimally invasive, image-guided parenteral route for drug administration, enhancing treatment precision. The increasing number of chemotherapy sessions worldwide, driven by growing cancer cases, underscores the demand for such implants. Their ability to deliver targeted therapies with reduced impact on healthy tissues positions them as a critical tool in oncology, further accelerating market growth during the forecast period.

Aging Population

The global geriatric population, projected by the United Nations to double to 1.5 billion by 2050, is a key driver. Older individuals are more prone to conditions requiring drug-eluting implants, such as cardiovascular diseases and cancer, increasing market demand. This demographic shift amplifies the need for advanced treatment options, positioning drug-eluting implants as a vital solution in addressing age-related health challenges.

Geographical Outlook

The Asia-Pacific region is expected to experience significant market growth, driven by its expanding geriatric population and rising prevalence of diabetes and cancer. North America and Europe continue to lead due to high adoption rates and advanced healthcare infrastructure, but Asia-Pacific's rapid healthcare advancements and large patient base make it a high-growth region through 2030.

Competitive Landscape

Key players, including iVascular, ProMed Pharma, LLC, Johnson & Johnson, Boston Scientific Corporation, The Merck Group, Medtronic, Inc., Biosensors International Group, Abbott Laboratories, Elixir Medical Corporation, and Siemens Healthcare, are driving innovation through strategic partnerships and product development. For instance, in May 2023, iVascular received CE mark approval for its iCover balloon-expandable covered stent, enhancing vascular treatment options.

Market Outlook

The drug-eluting implants market is set for robust growth through 2030, propelled by rising chronic disease prevalence, an aging population, and R&D advancements. Asia-Pacific's rapid expansion, alongside North America and Europe's dominance, underscores the market's global potential. Stakeholders must focus on innovation and scalability to meet growing demand while addressing cost-related challenges.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Market Segmentation:

By Product Type

  • Drug Eluting Stents
  • Contraceptive Implants
  • Drug Eluting Vascular Grafts
  • Others

By Material

  • Biodegradable
  • Non-Biodegradable

By Application

  • Oncology
  • Ophthalmology
  • Cardiology
  • Contraception/Birth Control
  • Others

By End-User

  • Hospital
  • Ambulatory Surgical Centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. DRUG ELUTING IMPLANTS MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Drug Eluting Stents
  • 5.3. Contraceptive Implants
  • 5.4. Drug Eluting Vascular Grafts
  • 5.5. Others

6. DRUG ELUTING IMPLANTS MARKET BY MATERIAL

  • 6.1. Introduction
  • 6.2. Biodegradable
  • 6.3. Non-Biodegradable

7. DRUG ELUTING IMPLANTS MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Oncology
  • 7.3. Opthalmology
  • 7.4. Cardiology
  • 7.5. Contraception/Birth Control
  • 7.6. Others

8. DRUG ELUTING IMPLANTS MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospital
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Others

9. DRUG ELUTING IMPLANTS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. USA
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. Germany
    • 9.4.2. France
    • 9.4.3. United Kingdom
    • 9.4.4. Italy
    • 9.4.5. Spain
    • 9.4.6. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Israel
    • 9.5.4. Others
  • 9.6. Asia Pacific
    • 9.6.1. China
    • 9.6.2. India
    • 9.6.3. Japan
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Taiwan
    • 9.6.8. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. iVascular
  • 11.2. ProMed Pharma
  • 11.3. Boston Scientific Corporation
  • 11.4. Merck Group
  • 11.5. Medtronic, Inc.
  • 11.6. Biosensors International Group
  • 11.7. Abbott Laboratories
  • 11.8. Elixir Medical Corporation
  • 11.9. Biotronik SE & Co. KG
  • 11.10. Lubrizol

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key benefits for the stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations